BackSienna Biopharmaceuticals Overview

Sienna Biopharmaceuticals Other Current Liabilities

Sienna Biopharmaceuticals's other current liabilities is $1.1M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.10M
89.30% YoYΔ $-9.22M vs prior year quarter

Peer trimmed avg / median

Loading

Sienna Biopharmaceuticals Other Current Liabilities History

Loading

Sienna Biopharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Sienna Biopharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sienna Biopharmaceuticals (SNNAQ) FAQ

As of the most recent data (September 2019), SNNAQ shows a other current liabilities of $1.1M. That compares with $10M in the prior-year period — down 89.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SNNAQ's other current liabilities is now $1.1M (was $10M) — a 89.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Sienna Biopharmaceuticals is outperforming or lagging.

Tracking SNNAQ's other current liabilities over time shows whether Sienna Biopharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $1.1M That compares with $10M in the prior-year period — down 89.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Sienna Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $1.1M) with ownership activity and broader fundamentals.

Sienna Biopharmaceuticals's other current liabilities is $1.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.